Advances in the development of hemostatic biomaterials for medical application

Abstract Background Medical hemostatic biological materials are necessary for the development of the process of preventing and stopping damaged intravascular bleeding. In the process, some red blood cells and white blood cells are trapped in nets. The resulting plug is called a blood clot. This is o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Kiel Sung, Dae Ryeong Lee, Dong June Chung
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Hemostasis Biomaterials Blood clotting Coagulation Wound healing Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/fb38a8936e564f5bab3b4c29280845f7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb38a8936e564f5bab3b4c29280845f7
record_format	dspace
spelling	oai:doaj.org-article:fb38a8936e564f5bab3b4c29280845f72021-11-14T12:07:52ZAdvances in the development of hemostatic biomaterials for medical application10.1186/s40824-021-00239-12055-7124https://doaj.org/article/fb38a8936e564f5bab3b4c29280845f72021-11-01T00:00:00Zhttps://doi.org/10.1186/s40824-021-00239-1https://doaj.org/toc/2055-7124Abstract Background Medical hemostatic biological materials are necessary for the development of the process of preventing and stopping damaged intravascular bleeding. In the process, some red blood cells and white blood cells are trapped in nets. The resulting plug is called a blood clot. This is often a good step in wound healing, but separation of blood clots from blood vessel walls can cause serious health problems. Main body The advance in the development of hemostatic biomaterials is necessary for biomedical application. Firstly, the historical background of artificial hemostasis has been included and the current research of hemostasis has been included in more detail. Secondly, the current research of hemostasis has been included on the oxidized cellulose-based hemostatic biomaterials such as starch based on composite cross-linking hemostatic networks, hemostatic materials on NHS-esters, hemostatic agent from local materials and biomaterials for hemostatic management. Thirdly, polysaccharide hemostatic materials, bio-inspired adhesive catechol-conjugated chitosan, mesoporous silica and bioactive glasses for improved hemostasis, minimally invasive hemostatic biomaterials and chitosan-base materials for hemostatic application have been included. Fourthly, the biological properties of natural hemostatic agent by plasma technology and the hemostatic agents based on gelatin-microbial transglutaminase mixes have been also included. Conclusion Current research on hemostasis includes hemostatic biomaterials such as cellulose-based hemostatic starch based on a complex cross-linked hemostatic network. It also includes polysaccharide hemostatic materials, biomimetic adhesive catechol-binding chitosan, mesoporous silica or physiologically active glass for hemostatic improvement, minimally invasive hemostatic chitosan-based materials, and gelatin-microbial transglutaminase-based hemostatic agents. Future studies should focus on modular combination of hemostatic imitation and reinforcement mechanisms of different materials and technologies to find the optimal system to promote and strengthen active platelet or platelet imitation aggregation in bleeding sites. The second optionally increases the production of thrombin and fiber formation at the site. Third, the formed fibrin biopolymer network has strengthened to reduce thrombosis and amplify hemostasis.Yong Kiel SungDae Ryeong LeeDong June ChungBMCarticleHemostasisBiomaterialsBlood clottingCoagulationWound healingMedical technologyR855-855.5ENBiomaterials Research, Vol 25, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Hemostasis Biomaterials Blood clotting Coagulation Wound healing Medical technology R855-855.5
spellingShingle	Hemostasis Biomaterials Blood clotting Coagulation Wound healing Medical technology R855-855.5 Yong Kiel Sung Dae Ryeong Lee Dong June Chung Advances in the development of hemostatic biomaterials for medical application
description	Abstract Background Medical hemostatic biological materials are necessary for the development of the process of preventing and stopping damaged intravascular bleeding. In the process, some red blood cells and white blood cells are trapped in nets. The resulting plug is called a blood clot. This is often a good step in wound healing, but separation of blood clots from blood vessel walls can cause serious health problems. Main body The advance in the development of hemostatic biomaterials is necessary for biomedical application. Firstly, the historical background of artificial hemostasis has been included and the current research of hemostasis has been included in more detail. Secondly, the current research of hemostasis has been included on the oxidized cellulose-based hemostatic biomaterials such as starch based on composite cross-linking hemostatic networks, hemostatic materials on NHS-esters, hemostatic agent from local materials and biomaterials for hemostatic management. Thirdly, polysaccharide hemostatic materials, bio-inspired adhesive catechol-conjugated chitosan, mesoporous silica and bioactive glasses for improved hemostasis, minimally invasive hemostatic biomaterials and chitosan-base materials for hemostatic application have been included. Fourthly, the biological properties of natural hemostatic agent by plasma technology and the hemostatic agents based on gelatin-microbial transglutaminase mixes have been also included. Conclusion Current research on hemostasis includes hemostatic biomaterials such as cellulose-based hemostatic starch based on a complex cross-linked hemostatic network. It also includes polysaccharide hemostatic materials, biomimetic adhesive catechol-binding chitosan, mesoporous silica or physiologically active glass for hemostatic improvement, minimally invasive hemostatic chitosan-based materials, and gelatin-microbial transglutaminase-based hemostatic agents. Future studies should focus on modular combination of hemostatic imitation and reinforcement mechanisms of different materials and technologies to find the optimal system to promote and strengthen active platelet or platelet imitation aggregation in bleeding sites. The second optionally increases the production of thrombin and fiber formation at the site. Third, the formed fibrin biopolymer network has strengthened to reduce thrombosis and amplify hemostasis.
format	article
author	Yong Kiel Sung Dae Ryeong Lee Dong June Chung
author_facet	Yong Kiel Sung Dae Ryeong Lee Dong June Chung
author_sort	Yong Kiel Sung
title	Advances in the development of hemostatic biomaterials for medical application
title_short	Advances in the development of hemostatic biomaterials for medical application
title_full	Advances in the development of hemostatic biomaterials for medical application
title_fullStr	Advances in the development of hemostatic biomaterials for medical application
title_full_unstemmed	Advances in the development of hemostatic biomaterials for medical application
title_sort	advances in the development of hemostatic biomaterials for medical application
publisher	BMC
publishDate	2021
url	https://doaj.org/article/fb38a8936e564f5bab3b4c29280845f7
work_keys_str_mv	AT yongkielsung advancesinthedevelopmentofhemostaticbiomaterialsformedicalapplication AT daeryeonglee advancesinthedevelopmentofhemostaticbiomaterialsformedicalapplication AT dongjunechung advancesinthedevelopmentofhemostaticbiomaterialsformedicalapplication
_version_	1718429444146724864

Advances in the development of hemostatic biomaterials for medical application

Ejemplares similares